A protein in urine may hold the key to helping doctors predict when a kidney will be rejected after a transplant.
A new clinical trial led by researchers at the University of Manitoba could change how kidney transplant patients are monitored, and potentially increase the longevity of the transplant.
"Those that lose their kidney transplants and they have to go back to dialysis, they actually have up to a three-fold higher risk of dying then if the transplants kept working," said Julie Ho, the principal researcher and a transplant physician.
- Winnipeg researcher makes predicting kidney failure easy with simple equation
- Lack of dialysis services in Northern Manitoba proving fatal, Indigenous patients say
Currently, around 12 to 15 per cent of patients experience kidney rejection in the first year after a transplant. Ho has been researching a protein found in urine that detects rejection much earlier than the current routine tests.
"We are hoping to prove that by using this test that we can detect rejection earlier and treat it earlier, and improve their outcomes at 12 months and hopefully over the long term," Ho said.
Following a kidney transplant, patients' urine will be tested for the CXCL10 protein. If it shows up there will be biopsy, and if that shows signs of rejection, the patient will receive treatment.
The five-year trials are expected to start in the coming weeks and have received a $2.6-million grant from the Canadian Institutes of Health Research.